Chemotherapy Response Rates Among XXXX With @entity1204 Who Have Elevated Serum Platelets.

@entity1 @entity1204 @entity1423 @entity5 @entity6962
OBJECTIVE: This retrospective study evaluates the influence of serum @entity1423 on chemotherapy response rates among @entity1 with @entity1204 . METHODS: From 3 separate @entity5 centers, a total of 318 @entity1 with @entity1204 who received postoperative chemotherapy between June 1999 and October 2009 were retrospectively identified. Endometrioid, serous, clear cell, and @entity6962 histologies were included. @entity1 were classified as having an @entity1423 if their serum @entity1423 was greater than 400 * 10/L at the time of initial diagnosis. Primary outcome was chemotherapy response, classified as either complete or partial/refractory. Secondary outcomes were disease-free and disease-specific survival.    Test and Student t test were performed as appropriate. Kaplan-Meier curves and Cox proportional hazards models were used to assess serum platelet effect on survival. RESULTS: There were 125 deaths, 76 recurrences, and 48 disease progressions. Of the total group, 53 (16.7%) were categorized as having an @entity1423 . An @entity1423 was associated with a lower chemotherapy response rate in univariate analysis (hazard ratio [HR], 2.8; 95% 95% confidence interval [CI], 1.46-5.38; P < 0.01). Multivariate analysis showed elevated platelets to be independently associated with decreased disease-free survival (HR, 2.24; 95% CI, 1.26-3.98; P < 0.01) but not disease-specific survival (HR, 1.03; 95% CI, 0.56-1.88, P = 0.93). CONCLUSIONS: @entity1 with @entity1204 who have an elevated serum @entity1423 greater than 400 * 10/L may have lower chemotherapy response rates and are at increased risk for recurrence when compared with @entity1 with a count within the reference range.
